Table 5 MDR analysis of SNP-SNP interaction.

From: The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis

Model

Bal. Acc. CV Training

Bal. Acc. CV Testing

CV Consistency

Accuracy

Sensitivity

Specificity

OR(95%CI)

P

rs1053049

0.538

0.513

8/10

0.537

0.593

0.481

1.35(1.06–1.74)

0.017

rs1053049, rs2206030

0.554

0.512

5/10

0.550

0.646

0.454

1.52(1.18–1.95)

0.001

rs2920503, rs1053049, rs2206030

0.573

0.471

2/10

0.566

0.554

0.578

1.70(1.33–2.18)

<0.001

rs2920503, rs4073770, rs2016520, rs2206030

0.602

0.500

7/10

0.597

0.646

0.548

2.22(1.72–2.85)

<0.001

rs2920503, rs4073770, rs1151988, rs2016520, rs2206030

0.630

0.500

5/10

0.624

0.601

0.646

2.76(2.14–3.55)

<0.001

rs2920503, rs4073770, rs1151988, rs67056409, rs1053049, rs2206030

0.658

0.506

10/10

0.650

0.751

0.550

3.68(2.82–4.80)

<0.001

rs2920503, rs4073770, rs1151988, rs2016520, rs67056409, rs1053049, rs2206030

0.668

0.4951

10/10

0.660

0.751

0.570

3.98(3.05–5.20)

<0.001

  1. MDR, multifactor dimensionality reduction; SNP, single nucleotide polymorphism; CV, cross-validation; OR, odds ratio; CI, confidence interval.
  2. Bold values indicate statistical significance (P < 0.05).
Back to article page